Applied Genetic Technologies (AGTC +0.5%) shrugs off broad market selling in early trade (albeit on very light volume). Shares have rallied 56% since December 18 ahead of two expected data readouts this month.
Interim six-month data from the expansion group in a Phase 1/2 study evaluating its recombinant adeno-associated virus vector (rAAV2tYF-GRK1-RPGR) in patients with X-linked retinitis pigmentosa caused by RPGR mutations.
Interim six-month dose-escalation data from Phase 1/2 studies evaluating gene therapy AGTC-402 in CNGA3 achromatopsia and CNGB3 achromatopsia (color blindness).
The company plans to present comprehensive data on all the trials at its R&D Day on Tuesday, January 28.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.